Such studies are important to reveal potential benefits and consequences of PAD inhibition, since PAD inhibitors have been proposed as therapeutic agents for the treatment of diseases in which citrullination is thought to be pathogenic, including rheumatoid arthritis, lupus, cardiovascular disease, thrombosis, multiple sclerosis, and cancer [21, 22]. This evidence concerns the gene PADI4 and multiple sclerosis.